| Followers | 3 |
| Posts | 1176 |
| Boards Moderated | 0 |
| Alias Born | 03/02/2018 |
Wednesday, March 06, 2019 12:22:00 AM
How many of us here now remember this?
From Seeking Alpha July, 2017
Delcath Systems Share Price Has Risen Over 1000% In The Past Month On No News And Is Engaged In Death Spiral Financing
Jul. 12, 2017 11:04 AM•DCTH
Summary
In the past month, Delcath has risen 1000% on promotional hype and no fundamental news.
It's engaging in death spiral financing, and the convertible note holders can buy shares at a 15% discount to the recent market price and immediately sell.
Delcath’s outstanding share count went from 39 million on February 10, 2017, to 374.4 million on June 5th, 2017, to 439.8 million on July 5, 2017.
Delcath is conducting clinical trials on its same technology that the FDA failed to approve in 2013.
.
Despite being a struggling company, Delcath's high spending executives award themselves high salaries, fly first class, and its HQ is located in expensive midtown Manhattan.
From Seeking Alpha July, 2017
Delcath Systems Share Price Has Risen Over 1000% In The Past Month On No News And Is Engaged In Death Spiral Financing
Jul. 12, 2017 11:04 AM•DCTH
Summary
In the past month, Delcath has risen 1000% on promotional hype and no fundamental news.
It's engaging in death spiral financing, and the convertible note holders can buy shares at a 15% discount to the recent market price and immediately sell.
Delcath’s outstanding share count went from 39 million on February 10, 2017, to 374.4 million on June 5th, 2017, to 439.8 million on July 5, 2017.
Delcath is conducting clinical trials on its same technology that the FDA failed to approve in 2013.
.
Despite being a struggling company, Delcath's high spending executives award themselves high salaries, fly first class, and its HQ is located in expensive midtown Manhattan.
Recent DCTH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
